ChiCTR1800016098
结束
/
/
/
2018-05-02
/
/
Patients undergoing elective cardiac surgery (CABG, with/without valvular interventions) Pre-frail and Frail patients
擇期心臟手術前復康計劃研究: 隨機對照試驗
擇期心臟手術前復康計劃研究: 隨機對照試驗
In patients undergoing primary elective cardiac surgery, does prehabilitation during the two months waiting period before surgery compared to no prehabilitation improve postoperative quality of recovery?
随机平行对照
Ⅲ期
Randomized
Single-blind for Investigator/research team
Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong; Local research grant by the General Research Fund (Pending)
/
164
/
2018-07-03
2023-10-31
/
1. Adults undergoing elective primary isolated coronary artery bypass grafting, aortic valve repair/replacement, mitral valve repair/replacement, or combined coronary artery bypass/valve procedures; 2. Prefrail to moderately frail patients with a Clinical Frailty Score of 4-6 at the time of accepting surgery at the outpatient cardiothoracic surgical clinic; 3. Patients with an estimated 8 or more weeks of surgical waiting list time; 4. Agreement on the suitability of the patient for prehabilitation with the attending cardiothoracic surgeon.；
请登录查看1. Patients with unstable or recently unstable cardiac syndrome (New York Heart Association Class IV, critical left main coronary disease, hospitalization for arrhythmias, congestive heart failure or acute coronary syndrome before randomisation); 2. Patients with severe left ventricular obstructive disease (severe aortic or mitral stenosis, dynamic left ventricular outflow obstruction); 3. Redo cardiac surgery; 4. Contraindications for prehabilitation (those with cognitive deficits unable to comply with study procedures, physical limitations precluding rehabilitation and inability to regularly attend outpatient prehabilitation sessions).；
请登录查看香港中文大學麻醉與重症監護部
/
香港中文大學麻醉與重症監護部的其他临床试验
香港中文大學麻醉與重症監護部的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04